AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study

This is a phase 1, single dose, randomised, double-blind, two-way crossover study to compare ultra-rapid-acting concentrated insulin aspart AT278 (U500/mL) with standard insulin aspart NovoRapid® (U100/mL) in participants with T2D.

Inclusion Criteria:Diagnosis of type 2 diabetes for at least 180 days prior to the day of screeningHaemoglobin A1C (HbA1c) concentration of ≤9.5% (≤80 mmol/mol) at screening.BMI within the range of 25 - 45 kg/m2 (both inclusive)Exclusion Criteria:Known or suspected hypersensitivity to IMPs or related productsClinically significant concomitant disease or abnormal lab valuesSevere asthma or chronic obstructive pulmonary disease (GOLD III and IV), or lower if requiring high dose of corticosteroids or beta2-adrenergic agonists